Whanin Pharm환인제약

Whanin Pharm016580· Biotech & PharmaUpdate note

Whanin Pharm Q3 2026 Preliminary Earnings: Operating Profit More Than Doubles Year on Year

Whanin Pharm reported Q3 2026 preliminary consolidated operating profit of ₩7.5B, up 111.8% from a year earlier, on revenue of ₩71.6B. The result supports the earnings-recovery picture in the previous report, though profit slipped from the prior quarter and our model estimate is lower than before.

Oct 29, 20260 views